Nano Dimension signs non-binding term sheet to acquire Infinite Epigenetics for $890M stock consideration

Nano Dimension Ltd.

Infinite valued at $890M; Nano valuation based on net cash plus 20% premium plus ~$20M for Essemtec.
Post-closing, Infinite shareholders to own majority; if >55%, they designate 5 of 7 board seats.
Nano will spin off legacy assets via CVR to pre-closing Nano shareholders.
Term sheet includes 30-day exclusivity; no definitive agreement yet.
Nano to reimburse Infinite up to $3M expenses if definitive deal not signed by EGM date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.